

Supplementary material

Hepatic NAD⁺ deficiency as a therapeutic target for NAFLD in aging

Can-Can Zhou^{1*}, Xi Yang^{1*}, Xia Hua,^{1*} Jian Liu², Mao-Bing Fan¹, Guo-Qiang Li¹, Jie Song¹, Tian-Ying Xu,¹ Zhi-Yong Li¹, Yun-Feng Guan,¹ Pei Wang,^{1#} Chao-Yu Miao^{1#}

Authors' Affiliations:

¹Department of Pharmacology, Second Military Medical University, Shanghai, China

²Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China

***These authors contribute equally to this work**

#Correspondence should be addressed to:

Chao-Yu Miao, MD, PhD, or Pei Wang, MD, PhD

Department of Pharmacology, Second Military Medical University, Shanghai, China

Tel: 86-21-81871271; Fax: 86-21-65493951

Email: cymiao@smmu.edu.cn or pwang@smmu.edu.cn

Supplementary Figure 1






Illustration of NAD⁺ *de novo* and salvage biosynthesis pathway. NAMPT is the step-limiting enzyme for salvage biosynthesis, whereas NADS and NMNAT are two important enzyme for NAD⁺ *de novo* biosynthesis.

Supplementary Figure 2




Decline of NAD⁺ pool in DN-NAMPT mice. (A) Endogenous NAMPT protein expression in WT and DN-NAMPT mice. **P* < 0.05 by Student's *t*-test. *n* = 8 for each group. (B) Detecting his-tag in WT, NAMPT and DN-NAMPT transgenic mice. (C) Liver NAD⁺ levels in liver tissues of WT and DN-NAMPT mice. **P* < 0.05 by Student's *t*-test. *n* = 8 for each group. (D) Body weight, liver weight and liver/body weight ratio in WT and DN-NAMPT mice. **P* < 0.05 by Student's *t*-test. *n* = 8 for each group.

Supplementary Figure 3




Macrophages isolated from WT and DN-NAMPT mice. (A) Representative images of isolated and cultured primary macrophages from WT and DN-NAMPT mice. (B) Endogenous NAMPT detection using a specific antibody against full-length NAMPT. $*P < 0.05$ by Student's t-test. $n = 6$ for each group. (C) Intracellular NAD⁺ levels in macrophages isolated from WT and DN-NAMPT mice. $*P < 0.05$ by Student's t-test. $n = 6$ for each group. (D) Determination of TNF- α and IL-6 release from macrophages isolated from WT and DN-NAMPT mice. $*P < 0.05$ by Student's t-test. $n = 6$ for each group. NS, no significance.

Supplementary Figure 4




NLRP3 inflammasome pathway in livers of WT and DN-NAMPT mice under normal chow. (A) Representative images of isolated and cultured primary macrophages from WT and DN-NAMPT mice. (B) Endogenous NAMPT detection using a specific antibody against full-length NAMPT. $*P < 0.05$ by Student's t-test. $n = 6$ for each group. (C) Intracellular NAD^+ levels in macrophages isolated from WT and DN-NAMPT mice. $*P < 0.05$ by Student's t-test. $n = 6$ for each group. (D) Determination of $\text{TNF-}\alpha$ and IL-6 release from macrophages isolated from WT and DN-NAMPT mice. $*P < 0.05$ by Student's t-test. $n = 6$ for each group. NS, no significance.

Supplementary Figure 5




Decline of NAD⁺ pool in HFD-induced NAFLD mice and DN-NAMPT mice and lipid profiles in HFD-fed WT and DN-NAMPT mice. (A) Liver NAD⁺ levels in liver tissues of HFD-induced NAFLD mice. The mice were fed with HFD for 16 weeks. **P* < 0.05 by Student's t-test. *n* = 8 for each group. (B-C) Decline of NAMPT protein in plasma (B) and liver (C) of NAFLD mice. **P* < 0.05 by Student's t-test. *n* = 8 for each group. (D-E) Expression of triglyceride and cholesterol efflux genes in HFD-fed WT and DN-NAMPT mice. **P* < 0.05 by Student's t-test. *n* = 8 for each group.

Supplementary Figure 6




SIRT1 mRNA and protein levels in WT and DN-NAMPT mice under normal chow or HFD. (A) SIRT1 mRNA level in livers of WT and DN-NAMPT mice. NS, no significance. n = 6 for each group. (B) SIRT1 protein level in livers of WT and DN-NAMPT mice. NS, no significance. n = 6 for each group.

Supplementary Figure 7



SIRT1 activity in WT and DN-NAMPT mice under normal chow or HFD. (A) SIRT1 activity in liver tissues of WT and DN-NAMPT mice under control and NAFLD conditions. $*P < 0.05$ by Student's t-test. $n = 8$ for each group. **(B)** Acetylation of LXR in liver tissues of WT and DN-NAMPT mice under control and NAFLD conditions. $*P < 0.05$ by Student's t-test. $n = 6$ for each group.


Supplementary Figure 8



Adenovirus-mediated SIRT1 overexpression in liver tissue of DN-NAMPT mice.

Representative image and quantitative analysis of adenovirus-mediated SIRT1 overexpression in liver tissue of DN-NAMPT mice. * $P < 0.05$ by Student's t-test. $n = 4$ for each group.

Supplementary Figure 9



NR treatment enhances hepatic NAD⁺ level in HFD-fed mice. * $P < 0.05$ by Student's t-test. n = 6 for each group.

Supplementary Table1

Clinical information for the patients with hepatectomy

Group	Number	Age	Gender	Hepatectomy indication	Hepatitis B virus infection
Age < 45	1	43	Male	Hepatocellular carcinoma	+
	2	29	Male	Hepatocellular carcinoma	+
	3	36	Female	Hepatocellular carcinoma	+
	4	37	Male	Hepatocellular carcinoma	+
	5	42	Female	Hepatosolithiasis	-
	6	45	Male	Hepatocellular carcinoma	+
Age > 60	7	62	Male	Hepatocellular carcinoma	+
	8	63	Female	Hepatocellular carcinoma	+
	9	65	Male	Hepatosolithiasis	-
	10	66	Female	Hepatocellular carcinoma	+
	11	67	Male	Hepatocellular carcinoma	+
	12	71	Female	Hepatosolithiasis	-

Supplementary Table2**Sequences of primers for PCR analysis**

Gene	Forward Primer	Reverse Primer
<i>ABCA1</i>	GCTGCAGGAATCCAGAGAAT	CATGCACAAGGTCCTGAGAA
<i>ABCG5</i>	AGGGCCTCACATCAACAGAG	GCTGACGCTGTAGGACACAT
<i>ABCG8</i>	TCCGAGGAGAACAAGCTGTC	TCCGAGGAGAACAAGCTGTC
<i>ABCG1</i>	CCGATGTGAACCCGTTTCT	AGGCGGAGTCCTCTTCAGC
<i>ApoB</i>	TTGGCAAACCTGCATAGCATCC	TCAAATTGGGACTCTCCTTTAGC
<i>MTP</i>	GGAAGGCTTAATTGCAGCCA	TTCAGCCTTGTCCATCTGCAT
<i>CD36</i>	ATTAATGGCACAGACGCAGC	CCGAACACAGCGTAGATAGACC
<i>FABP1</i>	CAGAGCCAGGAGAACTTTCAG	GATTTCTGACACCCCCTTGATG
<i>LDL-R</i>	AGTGGCCCCGAATCATTGAC	CTAACTAAACACCAGACAGAGGC
<i>SREBP-2</i>	GCAGCAACGGGACCATTCT	CCCCATGACTAAGTCCTTCAACT
<i>HMGCR</i>	CATCATCCTGACGATAACGCG	AGGCCAGCAATACCCAGAATG
<i>PCSK9</i>	GAGACCCAGAGGCTACAGATT	AATGTACTCCACATGGGGCAA
<i>α-SMA</i>	G TTCAGTGGTGCCTCTGTCA	ACTGGGACGACATGGAAAAG
<i>TIMP-1</i>	AGGTGGTCTCGTTGATTCGT	GTAAGGCCTGTAGCTGTGCC
<i>TGFβ-1</i>	TTGCCCTCTACAACCAACACAA	GGCTTGCGACCCACGTAGTA
<i>Pro-Collα1</i>	GACATCCCTGAAGTCAGCTGC	TCCCTTGGGTCCCTCGAC
<i>GAPDH</i>	GTATGACTCCACTCACGGCAAA	GGTCTCGCTCCTGGAAGATG